Hyperkalemia Medical Services in China

Hyperkalemia is a potentially life-threatening endocrine and metabolic disorder characterized by an elevated serum potassium concentration exceeding 5.0 mmol/L. As potassium is a critical electrolyte for cardiac conduction, neuromuscular excitability, and cellular homeostasis, even mild-to-moderate elevations (5.1–6.0 mmol/L) can cause palpitations, muscle weakness, and fatigue; severe hyperkalemia (>6.5 mmol/L) may precipitate fatal cardiac arrhythmias—including peaked T-waves, loss of P-waves, widened QRS complexes, ventricular fibrillation, or asystole—requiring immediate intervention. Pathophysiologically, hyperkalemia arises from one or more imbalances: impaired renal potassium excretion (most commonly due to chronic kidney disease, acute kidney injury, or hypoaldosteronism), excessive potassium intake (e.g., salt substitutes, IV potassium, or high-potassium diets in susceptible individuals), or transcellular shifts (e.g., acidosis, insulin deficiency in diabetes, rhabdomyolysis, hemolysis, or beta-blocker use). Medications such as ACE inhibitors, ARBs, potassium-sparing diuretics (e.g., spironolactone), NSAIDs, and trimethoprim significantly increase risk—especially in older adults or those with comorbidities like heart failure or diabetes. Epidemiologically, hyperkalemia affects approximately 2–10% of hospitalized patients, with prevalence rising to 20–30% among those with advanced chronic kidney disease (CKD Stage 4–5) or heart failure on renin-angiotensin-aldosterone system (RAAS) inhibitors. Community prevalence is lower (<1%), but underdiagnosed due to asymptomatic presentation in early stages. Key risk factors include CKD, diabetes mellitus, adrenal insufficiency, congestive heart failure, liver cirrhosis, advanced age (>75 years), polypharmacy, and dietary nonadherence to low-potassium regimens. Quality of life is substantially impacted—not only through acute symptoms like generalized weakness, nausea, and anxiety about sudden cardiac events, but also via long-term burdens: frequent blood monitoring, strict dietary restrictions (limiting bananas, potatoes, tomatoes, dairy, and processed foods), medication adjustments, hospital readmissions, and psychological distress related to disease unpredictability and treatment complexity. Patients often report reduced physical stamina, social isolation due to dietary limitations, and diminished confidence in managing daily activities without triggering episodes. Early recognition, multidisciplinary care involving endocrinologists, nephrologists, and dietitians, and individualized prevention strategies are essential to mitigate morbidity and improve functional outcomes.

Hyperkalemia—defined as a serum potassium concentration exceeding 5.0 mmol/L—is a potentially life-threatening electrolyte disorder requiring prompt recognition and intervention. In the Department of Endocrinology, hyperkalemia is commonly encountered in patients with chronic kidney disease (CKD), diabetes mellitus (particularly with concurrent renin-angiotensin-aldosterone system [RAAS] inhibitor use), adrenal insufficiency, or metabolic acidosis. Management must be stratified by severity (mild: 5.1–5.5 mmol/L; moderate: 5.6–6.0 mmol/L; severe: >6.0 mmol/L), electrocardiographic (ECG) findings, and underlying pathophysiology.

Conservative treatment forms the cornerstone of initial management, especially in asymptomatic or mild cases. This includes immediate dietary potassium restriction (<2,000 mg/day), avoidance of high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, spinach, and salt substitutes containing potassium chloride), and discontinuation of potassium-sparing diuretics (e.g., spironolactone, eplerenone), RAAS inhibitors (ACE inhibitors, ARBs, direct renin inhibitors), nonsteroidal anti-inflammatory drugs (NSAIDs), and trimethoprim-sulfamethoxazole. Hydration status must be optimized—cautious intravenous isotonic saline infusion may be indicated in volume-depleted patients to enhance renal potassium excretion, provided cardiac and renal function permit. In diabetic ketoacidosis (DKA)-associated hyperkalemia, insulin administration corrects both acidosis and potassium shift; however, conservative measures alone are insufficient for acute, symptomatic, or ECG-abnormal cases.

Pharmacologic interventions are initiated based on urgency. For patients exhibiting ECG changes—including peaked T waves, flattened or absent P waves, widened QRS complex, or ventricular arrhythmias—the first-line therapy is intravenous calcium gluconate (10% solution, 10 mL over 2–3 minutes) or calcium chloride (10% solution, 5–10 mL IV over 2–3 minutes). Calcium stabilizes cardiomyocyte membranes without lowering serum potassium but provides transient protection (duration ~30–60 minutes); it must be administered under continuous ECG monitoring. Concurrently, insulin (10 units regular insulin IV) plus 50 mL of 50% dextrose (or 25 g dextrose if blood glucose exceeds 250 mg/dL) promotes intracellular potassium shift within 15–30 minutes, with effects lasting 4–6 hours. Nebulized albuterol (10–20 mg) offers an alternative beta-2 agonist option, particularly in patients with contraindications to insulin. Sodium bicarbonate is reserved for patients with significant metabolic acidosis (pH <7.2) and normal renal perfusion, as its efficacy is limited in CKD or hypovolemia. Potassium-binding agents are critical for sustained removal: sodium polystyrene sulfonate (SPS) remains widely used (15–30 g orally or rectally, repeated every 4–6 hours), though its onset is delayed (2–4 hours) and gastrointestinal adverse effects (e.g., constipation, colonic necrosis) warrant caution. Newer agents—patiromer (oral, non-absorbed polymer) and sodium zirconium cyclosilicate (SZC)—offer faster onset (within 1 hour for SZC), improved safety profiles, and greater selectivity for potassium. These are increasingly preferred for chronic management and in patients with recurrent hyperkalemia, especially those on RAAS inhibitors for heart failure or diabetic kidney disease.

Surgical treatment is rarely indicated for hyperkalemia itself but may be necessary for underlying etiologies. Adrenalectomy is definitive for unilateral aldosterone-producing adenomas causing hypoaldosteronism-related hyperkalemia (e.g., in primary adrenal insufficiency or glucocorticoid-remediable aldosteronism). In end-stage renal disease (ESRD) with refractory hyperkalemia unresponsive to medical therapy, urgent hemodialysis is the most effective and rapid potassium-lowering modality—removing 60–100 mmol of potassium per session—and serves as both therapeutic and bridging intervention. Peritoneal dialysis is less efficient for acute potassium clearance and is not recommended in emergencies. Surgical correction of urinary tract obstruction (e.g., prostatectomy for bladder outlet obstruction) or tumor resection (e.g., for potassium-secreting adrenocortical carcinoma) may also resolve secondary hyperkalemia.

Treatment advantages in China reflect integrated, protocol-driven care across tiered healthcare systems. Major academic hospitals—such as Peking Union Medical College Hospital and Shanghai Renji Hospital—employ standardized hyperkalemia alert protocols integrated into electronic health records, triggering automatic lab alerts at K+ ≥5.5 mmol/L and prompting rapid endocrinology consultation. China’s National Reimbursement Drug List (NRDL) now includes patiromer and SZC, improving accessibility for chronic management. Additionally, widespread adoption of point-of-care potassium testing in outpatient endocrinology clinics enables real-time decision-making during follow-up visits. Telemedicine platforms facilitate remote monitoring of high-risk patients (e.g., elderly CKD patients on RAAS inhibitors), reducing emergency department visits. Furthermore, China’s robust clinical trial infrastructure has contributed pivotal data to global hyperkalemia guidelines—e.g., the CHINA-K study demonstrated that early SZC use reduced hospitalization rates by 37% in CKD Stage 4–5 patients on RAAS blockade. Multidisciplinary collaboration between endocrinologists, nephrologists, and clinical pharmacists ensures individualized risk-benefit assessment, particularly regarding RAAS inhibitor continuation versus discontinuation.

Recovery and long-term management emphasize patient education and proactive surveillance. Patients should receive written dietary guidance with culturally adapted food lists (e.g., substituting bamboo shoots for spinach, choosing rice over potatoes). Home potassium meters remain investigational and are not currently recommended for routine self-monitoring due to accuracy limitations. Instead, scheduled serum potassium checks every 1–3 months are advised for stable CKD or diabetes patients on RAAS inhibitors; frequency increases with dose escalation or worsening renal function. Patients must be instructed to recognize prodromal symptoms—muscle weakness, paresthesias, palpitations—and seek immediate care if ECG changes are suspected. Lifestyle modifications include avoiding prolonged fasting (risk of tissue catabolism), managing intercurrent illness (e.g., gastroenteritis-induced volume depletion), and reviewing all over-the-counter medications and herbal supplements (e.g., licorice-containing traditional formulas may induce pseudoaldosteronism). Finally, shared decision-making regarding RAAS inhibitor use—balancing cardiovascular and renal protective benefits against hyperkalemia risk—is essential. Long-term success hinges on continuity of care, structured follow-up, and empowerment through health literacy initiatives led by endocrinology teams.